Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you. Great update for new investors. Also. I love the speed in which the trial has picked up. I said it before this started. If it starts to pick up......that is a very very very good sign and can tip us off on progress. This may be a unicorn moment. Imo
I personally believe full buyout will happen after this trial. It’s the only thing that makes sense to me.
I will promise you. There is no need to save this company from Bankruptcy.
There are very valuable drugs in this pipeline. Leo is holding and not giving in until he further proves the robust multi indication capabilities.
Antibiotic
AntiViral
AntiInflamatory
Etc
UC, Crohns, UP OM, Virus, etc.
I’m looking forward to adding value here with this antiviral testing.
If anything....he can reverse split. So don’t give me this Bankrupt bs
Great post. Thank you. This thought and belief to why we are invested here is exactly why people should be excited. We are months away from finding out
She seemed very enthusiastic on Remdemisvir and B as combo.
Come on Gilead
Good news. Exactly what we could have hoped for. No safety concerns and increase in possible revs
Thank you. David is an honest man and works hard. Probably why the new Exec team kept him on board. Hope to see news prior to month end.
Atleast the updated IR page happened. Check that box
Several tweets about product launch coming.
Anyone have info on pricing? Single serving dose, so can’t be too expensive. The bottle and manufacturing can’t be cheap IMO. Wonder what margins will be per bottle.
KOAN
Just checking in. I see a drift down after the trial start. Well......let’s go Leo!
Stir up a frenzy
Thank you. If the product is good. And the product does what each says. It’s a slam dunk.
This stock has no volume. 100k plus is a huge day which will change once the product is out there. I’d hope to see cards placed in purchase bags with KOAN ticker and posters within the dispensaries.
If they go big on this launch I’d expect new eyes and much more volume. This is an extremely tightly held stock.
If it goes up from .20 to .90 on very little volume and retraces easily on same. That shows you everything.
Let’s hope for an EXTREMELY WELL ORCHESTRATED AND PROMOTED LAUNCH.
KOAN
So many young investors are loving pot stocks and this one is not even a blip
CALABASAS, Calif.--(BUSINESS WIRE)--Resonate Blends, Inc. (OTCQB:KOAN), a Wellness Lifestyle cannabis holding company (“Resonate” or “the Company”), announced today it has closed its private placement raising $3,312,500 in gross proceeds. After paying finder fees of $288,213 to its placement agent, the Company netted $3,024,287 which provides some of the needed capital to launch Resonate’s first value-added cannabis-based KOAN® Cordials. The Cordials are designed to be uniquely formulated, single serving, precisely targeted experiences that are directly ingested or mixed with a drink for use in social or private settings.
The proceeds from the private placement were also used to retire the Company’s remaining Promissory Convertible Notes, pay off vendor obligations and to provide general working capital. The Company worked diligently the past year to align the capital structure of the public company to the financial requirements of its operating entities.
“We have worked diligently to get to this point and are extremely excited as we plan for our full scale production of our highly anticipated KOAN® Cordials product line with six unique formulations later this month. Given our corporate philosophy that our capital structure, strategic focus and quality of employees are the 3 legs upon which to build a great company, we are delighted to announce that the capital structure is aligned with the needs of our product launch and evolving product roadmap. Our goal has been to establish a broad network of strategic investors committed to our long term growth and values who support the management team and vision. The success of this round of funding has provided precisely that. We look forward to working with this network and others to build a next generation cannabis company founded on the idea that the future of cannabis will be value-added brands supporting the Wellness Lifestyle through the integration of art and science in service of extraordinary products.”
The securities mentioned will not be or have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Every day that passes is a day closer to PHASE 2 Covid results. I’m hopeful Brilacidin will steal the spotlight.
I’m reading more and more about future viruses. Hopefully B steps up
KEVETRIN! Come back to us!
Watch carefully to see enrollment and how fast we bring on sites. If a few patients look good, the hospitals will push patients imo. I’m hopeful.
It more revenue atleast. ;)
I’m hopeful we start to see trial enrollment increase at a high pace...this would mean good results. IMO.
I wonder why. Because 5 day is the SOC? What happens if B is better in shorter duration
UC is on deck and is by far multiples x in possible value. Not a bad plan B. OM needs a partner because it’s phase 3.
I’m guessing we have some interest. But Leo is holding out until Covid/antiviral and UC oral.
I’m not happy about the 58 million shares added to the OS in Jan/Feb and the 13 to aspire over past months. I hate this dilution but it’s needed to keep moving forward. If we can stay at 420 and get a real partner, soon....we will be fine. Otherwise, I think a RS will come in the next 2years. And trust me...I do not want that.
Can we get a shareholder meeting together?????
I like this post. When I read it, some peace and clarity blanketed me. Thank you. It is true and this trial may help to ignite the belief. This work does need a drug like B
Lol. Come on. Good Management. Great looking product. (Looking). Best industry to be a part of.
Low float. Low OS.
The minute koan brings in a dollar this flys.
This launch and true product reviews will tell story. Tic toc gambi
They cashed in around 1.5 million?
Money is not free
Brilacidin. Big time increase in value coming. Get ready my friends for a life changer.....finally. ;)
Things are going to get interesting here over next 30 days. We should have interim data in March or April. No timeline but I’d hope latest by end of April.
If Brilacidin proves out as pre clinical data suggests, I’d say EUA is a given and I’d expect major government funding and manufacturing as standard of care.
All need to recognize. The vaccine hopes are good, but we don’t and won’t truly know for many months to a year(s) the effect it has on society. mRNA is brand new.
The vaccines may also help to create a very scary mutated virus. A doctor I know was telling me a possible outcome of all this quick new mRNA deployment. People may not have thought things thru on how this will affect us in 5 years. .
https://www.politico.com/news/2021/02/27/virginia-legalizes-marijuana-471840
Isn’t this our CIO’s old stomping grounds!
First state in the OLD SOUTH to approve.
MJ = KOAN
“Patients are being treated, with recruitment and enrollment progressing at trial sites.”
To be exact
Lol. I’ve been seeing that a lot here.
Low float. This will FLY on product release and Revs. Tic toc
I’ve had a rough time buying this over the past month. A few times I just slapped the ask like 5-7 cents above bid. Days and days on bid with nothing.
IMO. If product is as advertised and as beta users have scored it.....this is selling out quick.
~30 million OS is nothing if they can keep it there. I’d like to see several dollars by year end and uplist. Let’s have those MJ etfs sucking up these shares and holding.
Let’s go KOAN!!!!
Phenomenal info
Focus and don’t let the trolls make you second guess. Diamond grip baby.
Good point. More Revs.
Come on Maxxy???? No trial???
That statement is also unclear. Is that past tense or future?
“After an interim review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days.”
Great thoughts BF
Think about that. Alfa delivered news in January. We don’t know what date. Trials are on going and Leo said they are planned to start next week end of January.
Nothing since.
Lemoncat may have the most obvious reasoning. Deal in works. Good faith to not spark an uptick in price etc....
Probably and most likely not, BUT AS Dud said too....this whole thing is very very Leo unlike.
Deal baby. Deliver a phat deal
Further, a grant application for federally-funded research is pending, and further grant applications are planned.
Page 32 of Q
They key word is anticipated. 120 enrollment. We don’t know yet the final details.
WAKEFIELD, MA – November 16, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that an overseas Clinical Trial Application (CTA) has been submitted to the governing health agency, with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA. Both these submissions are part of final preparations for the Company’s multinational Phase 2 clinical trial of Brilacidin for COVID-19, which is on track to commence in 2020 upon gaining required approvals.
The randomized, double-blind, placebo-controlled, multi-center study is anticipated to enroll 120 hospitalized patients with COVID-19. Sufficient Brilacidin intravenous (IV) drug product has been manufactured to complete this trial, and potentially future COVID-19 trials, providing the Company with added flexibility as it develops Brilacidin for the treatment of COVID-19.
In other important news, the Company has been informed by researchers at George Mason University’s Regional Biocontainment Laboratory that new in vitro testing showed Brilacidin exerted similarly potent inhibition against two strains of SARS-CoV-2, the novel coronavirus responsible for COVID-19. These data suggest Brilacidin would likely not be susceptible to resistance developing due to SARS-CoV-2 mutations, unlike many other vaccines and antivirals currently in use and in development.
“Due to the rapid worldwide spread of the COVID-19 pandemic, the need for novel therapeutics to help control this disease has only increased,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “While we all hope for the expedient arrival of safe and effective COVID-19 vaccines, which is one part of the solution, the need for better therapeutics to treat this disease, including its different strains, also remains essential. Vaccines and therapeutics both will play integral roles in addressing the current COVID-19 pandemic and possible future viral pandemics. We are excited by Brilacidin’s potential to treat SARS-CoV-2 and look forward to the start of our upcoming clinical trial, as we continue to advance Brilacidin in the global fight against COVID-19.”
Agree. See you at .40 ;$
False. Oral UC will start this year and the reason Leo has raised 14million. That is a phase 2 trial. Huge potential for blockbuster potential